Search PubMed⌕ Search

Biomedical subjects

M Haid

Publications and source records attributed to M Haid.

28 records · Page 2Linked to original sources
PubMed1983

Effect of interferon therapy on indomethacin-sensitive immunoregulation in the peripheral blood mononuclear cells of renal cell carcinoma patients.

The effect of interferon (IFN) therapy on prostaglandin (PGE)-synthesizing immunoregulatory cell function was assessed in the peripheral blood mononuclear cells of renal cell carcinoma patients. Ten patients were treated daily for 28 days with either 1 X 10(6) IU (five patients) or 10 X 10(6) IU (five patients) of leukocyte IFN. Patient cells were assessed for phytohemagglutinin (PHA) responsiveness in the presence and absence of the PGE synthetase inhibitor indomethacin. Progressive impairment in PHA responsiveness was found in all patients by the end of 28 days of therapy. It was associated with increased levels of indomethacin-sensitive suppressor function. Change in any of the patients studied was not correlated with IFN dose level. There was no correlation between clinical response to IFN and alterations in these parameters of immune function. In co-culture experiments, preincubation of glass-adherent cells with IFN led to increased indomethacin-sensitive regulatory function. These results suggest that IFN can produce progressive impairment of PHA-induced lymphoproliferation by increasing PGE-synthesizing immunoregulatory cell activity.

Adenocarcinoma↗
PubMed1982

Breast carcinoma: expected results with prevailing therapy.

Computer-stored tumor registry data were scanned to produce the set of patients whose breast carcinoma was either diagnosed or first treated at Evanston Hospital between the years 1973 and 1977, inclusive. Of 560 evaluable patients, 184 were less than or equal to age 50 (LE 50), and 376 were greater than age 50 (GT 50). Comparisons of projected survival show that the survival of all patients is 8% at 5 years and 72% at 7 years. The survival of patients LE 50 is nearly identical to that of the GT 50 age group. Survival of Stage III GT 50 patients, however, is better than Stage III LE 50 (P less than 0.001). Comparison with earlier studies shows an historical trend toward better 5-year survival. Data were generated in this study which allow prediction of prognosis based upon age and stage at diagnosis.

Age Factors↗
PubMed1981

Bladder carcinoma.

Explore the source record for details and available documents.

Carcinoma, Transitional Cell↗
PubMed1981

Peritoneal washing therapy for pseudomyxoma peritonei.

Two patients with pseudomyxoma peritonei (PP) had repeated intraperitoneal washing with 5% dextrose in water. Both responded to this therapy with decrease in abdominal girth. The second patient is alive, without abdominal distention, more than 112 weeks since beginning peritoneal washing therapy (PWT) for ovarian PP. Biochemical assays of urine before and after PWT show that acid mucopolysaccharide is excreted in the urine, probably after being absorbed through the peritoneal surface. The long-term effects of this procedure on renal function are not known, but PWT appears to be reasonable and safe ambulatory therapy for PP.

Adenocarcinoma↗
PubMed1980

Urinary bladder metastases from breast carcinoma.

Four patients with primary carcinoma of the breast metastatic to the urinary bladder are described. Hematuria was present in 3 of the 4 patients. Two of the 4 women had received steroidal drugs which may have a role in the development of this unusual metastasis. This complication developed no sooner than 32 months after diagnosis of malignant breast disease and occurred shortly before death in 2 of the patients. Bladder metastasis in women with a history of breast carcinoma may be more prevalent than has previously been suspected.

Aged↗
PubMed1980

Liver scanning in newly diagnosed breast carcinoma.

The records of 111 consecutive cases of carcinoma of the breast were reviewed and yielded 66 patients who had undergone liver scanning and determination of the serum alkaline phosphatase (alk p'tase), lactic dehydrogenase (LDH), and serum glutamic oxaloacetic transaminase (SGOT). Four of the 66 patients (6.1%) had a focal defect on the liver scan. Two of those two had normal enzymes and two had at least one enzyme elevation. The two with normal enzymes have enjoyed prolonged disease-free survivals. The two with an elevated enzyme have both expired due to metastatic disease. No correlation could be found between the number of involved axillary nodes at surgery and the risk of having a focal defect on the liver scan. This study suggests that routine radionuclide liver scanning in the perimastectomy period does not add useful information in the face of normal alk p'tase, LSH, and SGOT.

Alkaline Phosphatase↗
PubMed1977

Thromboelastographic distinction of malignant from benign breast masses: a preliminary report.

Thromboelastography is a newly applied tool for the detection of carcinoma. By comparing the thromboelastograph (TEG) of fresh whole blood (native) to that of blood to which celite has been added (celite activated), enhanced clotting is manifested which allows identification of individuals harboring carcinoma. Twenty women, obtained in a random sampling, entering the North Carolina Baptist Hospital for biopsy of breast masses were studied with routine clotting tests and TEGs preoperatively. TEG prediction of the biopsy result was correct in 16 of 20 patients (P less than 0.05). Thromboelastography may be a useful adjunct in screening for carcinoma in the evaluating persons with masses of unknown histology.

Blood Coagulation Tests↗
PubMed1977

Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix.

Sixteen women with advanced carcinoma of the cervix were treated with adriamycin and methotrexate. Median age on entry into the study was 51 years. Seven subjects were premenopausal, 7 postmenopausal, and 2 were within 2 years of their last menstrual period at the time of diagnosis. Median time of inclusion in the study was 3.3 months. Median survival from initial diagnosis thus far has been 39.0 months. Median survival from the institution of therapy has been 5.8 months. Of 16 evaluable patients the following results were obtained: no complete remissions (0%), 2 partial remissions (12.5%), 1 patient with stable disease (6.2%). When used in dosages which do not precipitate dangerous toxicity this therapy is not effective and in the opinion of the authors should be abandoned.

Doxorubicin↗
PubMed1976

Thromboelastographic changes in carcinoma: an animal model.

The dynamics of blood clotting using a thrombelastogram (TEG) are depicted after the injection of V2 carcinoma cells or control heterologous peritoneal exudates in New Zealand hares. Changes in the TEG configurations of native blood samples vs. celite activated samples run simultaneously provide a qualitative assessment of the presence of carcinoma.

Animals↗